Back

The adaptive immune responses to SARS-CoV-2 as a recall response susceptible to immune imprinting

Alvarez-Sierra, D.; Martinez-Gallo, M.; Sanchez-Montalva, A.; Fernandez-Sanmartin, M. A.; Colobran, R.; Espinosa-Pereiro, J.; Poyatos-Canton, E.; Sanchez-Pla, A.; Zurera-Egea, C.; Violan, C.; Parra, R.; Halzayat, H.; Vivancos, A.; Morandeira-Rego, F.; Urban-Vargas, B.; Martinez-Caceres, E.; Hernandez-Gonzalez, M.; Bas-Minguet, J.; Teniente-Serra, A.; Katsikis, P.; Pujol Borrell, R.

2024-08-11 infectious diseases
10.1101/2024.08.11.24311358 medRxiv
Show abstract

BackgroundThe antibody response to SARS-CoV-2 does not follow the immunoglobulin isotype pattern expected in a primary response and is inconsistent with the current interpretation of COVID-19 immunopathology as the result of a primary infection. To better understand the immune response to SARS-CoV-2, it is essential to determine whether it is primary or secondary (or recall). The analysis of highly granular immunological variable trajectories of a homogeneous cohort of patients receiving standardised medical care should discern between primary and secondary responses. MethodsThis is a prospective cohort study of 191 SARS-CoV-2 infection cases and 44 healthy controls from the second wave of COVID-19 in the Barcelona area. The study stratified patients by severity and analysed the trajectories of SARS-CoV-2 antibodies and multiple immune variables for features associated with primary and recall immune responses. FindingsIsotype-specific antibody trajectories to SARS-CoV-2 proteins revealed a pattern of recall response in 94{middle dot}2% of cases. In these cases, the detailed trajectories of plasmablasts, B cells, cTfh high-resolution subsets, and cytokines were consistent with a secondary response. The transcriptomic data indicated that this cohort is strictly comparable to contemporary cohorts. ConclusionsIn most cases, the immune response to SARS-CoV-2 is a recall response. This opens the possibility that most COVID-19 cases are subjected to immune imprinting by endemic coronavirus, which, in turn, can contribute to severity by interfering with the immune response to SARS-CoV-2 and by antibody-dependent enhancement. Considering the immune responses to SARS-CoV-2 secondary provides a better perspective to interpret COVID-19 pathology. FundingGrants COV20/00416, Cov20/00654, and COV20/00388 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, co-financed by the European Regional Development Fund (ERDF).

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.6%
10.1%
2
BMC Medicine
163 papers in training set
Top 0.6%
6.3%
3
Infectious Diseases
14 papers in training set
Top 0.1%
4.2%
4
PLOS ONE
4510 papers in training set
Top 39%
3.6%
5
Nature Communications
4913 papers in training set
Top 40%
3.6%
6
The Journal of Infectious Diseases
182 papers in training set
Top 1%
3.6%
7
EBioMedicine
39 papers in training set
Top 0.1%
3.1%
8
Allergy
23 papers in training set
Top 0.2%
2.9%
9
Scientific Reports
3102 papers in training set
Top 44%
2.7%
10
BMJ Open
554 papers in training set
Top 7%
2.6%
11
eBioMedicine
130 papers in training set
Top 0.5%
2.6%
12
Clinical Microbiology and Infection
60 papers in training set
Top 0.4%
2.1%
13
Frontiers in Medicine
113 papers in training set
Top 3%
2.1%
14
Journal of Clinical Immunology
11 papers in training set
Top 0.1%
1.9%
50% of probability mass above
15
Journal of Clinical Medicine
91 papers in training set
Top 3%
1.9%
16
Clinical Infectious Diseases
231 papers in training set
Top 2%
1.9%
17
BMC Infectious Diseases
118 papers in training set
Top 2%
1.9%
18
Immunology
29 papers in training set
Top 0.4%
1.8%
19
iScience
1063 papers in training set
Top 15%
1.7%
20
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
1.5%
21
Viruses
318 papers in training set
Top 3%
1.5%
22
Epidemiology and Infection
84 papers in training set
Top 2%
1.3%
23
Clinical Immunology
21 papers in training set
Top 0.4%
1.2%
24
International Journal of Epidemiology
74 papers in training set
Top 2%
1.2%
25
Journal of Medical Virology
137 papers in training set
Top 3%
1.2%
26
European Journal of Immunology
57 papers in training set
Top 0.3%
1.2%
27
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.9%
28
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
29
European Respiratory Journal
54 papers in training set
Top 2%
0.8%
30
JCI Insight
241 papers in training set
Top 7%
0.7%